D DBV Technologies SA
D
Uždarymo kaina
2.32 0.09
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
2.278
Max
2.366
Pajamos | -2.8M -50M |
|---|---|
Pardavimai | -200K 700K |
Pelnas, tenkantis vienai akcijai | -0.05 |
Pelno marža | -7,200 |
Darbuotojai | 170 |
EBITDA | -1.2M -47M |
Kitas uždarbis | 2026-10-28 |
|---|
Rinkos kapitalizacija | -146M 687M |
|---|---|
Ankstesnė atidarymo kaina | 2.23 |
Ankstesnė uždarymo kaina | 2.32 |
DBV Technologies SA Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
DBV Technologies SA Prognozė
Finansinės naujienos
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$
Apie bendrovę DBV Technologies SA
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.